{"id":"https://openalex.org/W2013111506","doi":"https://doi.org/10.1016/s1359-6349(08)70079-x","title":"P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC","display_name":"P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC","publication_year":2007,"publication_date":"2007-11-01","ids":{"openalex":"https://openalex.org/W2013111506","doi":"https://doi.org/10.1016/s1359-6349(08)70079-x","mag":"2013111506"},"language":"en","primary_location":{"id":"doi:10.1016/s1359-6349(08)70079-x","doi":"https://doi.org/10.1016/s1359-6349(08)70079-x","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1359-6349(08)70079-x","pdf_url":null,"source":{"id":"https://openalex.org/S13410216","display_name":"European Journal of Cancer Supplements","issn_l":"1359-6349","issn":["1359-6349","1878-1217"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","jufo-1","norway-1","poland-100","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer Supplements","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064692327","display_name":"Ann Cleverly","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Cleverly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001557696","display_name":"Gerold Bepler","orcid":"https://orcid.org/0009-0009-6654-2471","observed_orcids":["https://orcid.org/0009-0009-6654-2471"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Bepler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Y. Oh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Oh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Burris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008593691","display_name":"Roy S. Herbst","orcid":"https://orcid.org/0000-0003-2535-5847","observed_orcids":["https://orcid.org/0000-0003-2535-5847"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R.S. Herbst","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5033549340","display_name":"Michael Lahn","orcid":"https://orcid.org/0000-0002-1377-7308","observed_orcids":["https://orcid.org/0000-0002-1377-7308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Lahn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"5","issue":"8","first_page":"30","last_page":"30"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.861299991607666,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.861299991607666,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.03799999877810478,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.032600000500679016,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/enzastaurin","display_name":"enzastaurin","score":0.9800000190734863},{"id":"https://openalex.org/keywords/protein-kinase-c-inhibition","display_name":"protein kinase C inhibition","score":0.8140000104904175},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.9440000057220459},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.7879999876022339},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.800000011920929},{"id":"https://openalex.org/keywords/tumor-vasculature","display_name":"tumor vasculature","score":0.9200000166893005},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8130000233650208},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9200000166893005},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.652999997138977},{"id":"https://openalex.org/keywords/rapamycin","display_name":"rapamycin","score":0.9490000009536743},{"id":"https://openalex.org/keywords/human-umbilical-vein-endothelial-cells","display_name":"human umbilical vein endothelial cells","score":0.7139999866485596},{"id":"https://openalex.org/keywords/ribosomal-protein-s6-phosphorylation","display_name":"S6 phosphorylation","score":0.8109999895095825}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6605152487754822},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6575040221214294},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.6073934435844421},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.5928178429603577},{"id":"https://openalex.org/C117262875","wikidata":"https://www.wikidata.org/wiki/Q5135057","display_name":"Clonogenic assay","level":3,"score":0.5604472160339355},{"id":"https://openalex.org/C2778608917","wikidata":"https://www.wikidata.org/wiki/Q6787805","display_name":"Matrigel","level":3,"score":0.5023846626281738},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48019421100616455},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.4574136435985565},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4431836009025574},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.36841702461242676},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.34587883949279785},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.31871476769447327},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24591809511184692},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.20458048582077026},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.14288806915283203},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s1359-6349(08)70079-x","doi":"https://doi.org/10.1016/s1359-6349(08)70079-x","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s1359-6349(08)70079-x","pdf_url":null,"source":{"id":"https://openalex.org/S13410216","display_name":"European Journal of Cancer Supplements","issn_l":"1359-6349","issn":["1359-6349","1878-1217"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","jufo-1","norway-1","poland-100","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer Supplements","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1984604008","https://openalex.org/W2066984870","https://openalex.org/W2132649906","https://openalex.org/W1999617811","https://openalex.org/W2046379396","https://openalex.org/W2148042737","https://openalex.org/W2098330972","https://openalex.org/W2519711126","https://openalex.org/W1898295405","https://openalex.org/W2466460675"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}